At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
RO7017773 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating RO7017773 and [11C] Ro15-4513 for Autism Spectrum Disorder. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedApr 2018
Primary CompletionJun 2018
TodayJul 2026
First PostedApr 25, 2018
Enrollment StartApr 24, 2018
Primary CompletionJun 22, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.2 years ago
Interventions
RO7017773drug
RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
[11C] Ro15-4513other
At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.